



ASX ANNOUNCEMENT

Actinogen Presentation at AAT-ADPD International Congress

Sydney, 29 April 2020. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to be able to share Actinogen's presentation following the recent **Advancement in Alzheimer's and Parkinson's Therapies Focus Meeting (AAT-AD/PD)**. This international scientific congress reviews the latest breakthroughs in drug development, translational R&D, early diagnosis, and clinical trials in Alzheimer's and Parkinson's disease with an audience of leading academic and biopharma industry experts, and for the first time in its history, the conference this year was held as a completely virtual event. Actinogen is proud to have contributed its data generated on Xanamem to this body of knowledge. The full presentation as presented by **Professor Craig Ritchie**, Chair of Actinogen's Xanamem Clinical Advisory Board, has been uploaded to the Actinogen website and can be found [here](#).

As the presentation was made to a medical congress and contained significant technical detail, a summary of the key highlights of the presentation has been uploaded and attached [here](#). The original slide presentation, without Professor Ritchie's recorded dialogue, is also available on the Company website, and [here](#).

As the unprecedented global crisis resulting from the COVID-19 outbreak continues to evolve, Actinogen is fortunate to be in a position to be between key active clinical trials and the progress on development activities has continued with limited disruptions through careful management. The Company is progressing the ongoing in-depth data analyses and future trial planning activities, in parallel to expanding discussions with potential key strategic parties, submitting and progressing grant applications, and continuing with other ongoing business development activities. This work will ensure Actinogen is well-placed to commit to a range of new and carefully designed studies once the current restrictions demanded by the health crisis are lifted.

Actinogen remains in a strong cash position, with no major capital commitments made for future studies. We are submitting numerous grant applications in relation to future clinical trials and continue to explore additional opportunities for non-dilutive funding as they arise. Corporate expenses are being minimised and carefully managed, and the global situation is being monitored.

Given the circumstances, the Company will continue to provide updates as appropriate to keep you informed.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Investor Enquiries

Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: Actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed platform biotechnology company developing an innovative treatment for cognitive impairment associated with chronic neurological and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia and mood disorders. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other therapies for Alzheimer's disease. It works by blocking the excess production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain, affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease and schizophrenia and in metabolic diseases like diabetes.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, showed that the drug exhibited a good safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant improvement in cognition, which, along with other data recently generated, confirms the underlying mechanism of action of Xanamem.

The Company plans to initiate Phase II studies of Xanamem against various diseases as soon as possible after the current COVID19 health crisis affecting the globe; including in Alzheimer's disease, and in cognitive impairment associated with schizophrenia and diabetes.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.